Waldencast’s Obagi Medical to present new data at ASDS annual meeting

Obagi Medical, a part of Waldencast (WALD), announced new data shared at the recent American Society for Dermatologic Surgery, ASDS, Annual Meeting, which took place November 13-16, 2025, in Chicago, Illinois. “Obagi Medical’s commitment to advancing dermatologic science and driving innovation is reflected in the data shared across our skincare and injectable portfolio at the recent ASDS meeting,” said Drew Fine, U.S. General Manager, Professional Channel. “New products with proven quality, a well-established safety profile, and high patient satisfaction are critical to expanding the aesthetic injectable market. The selection of the Obagi(R) saypha(R) ChIQ(TM) abstract as one of the top 10 for oral presentation highlights the powerful data supporting the new Obagi injectable.”